CAPPED BONUS CERTIFICATE - GALAPAGOS Stock CAPPED BONUS CERTIFICATE - GALAPAGOS
Add to a list
To use this feature you must be a member
Log inSign up

CAPPED BONUS CERTIFICATE - GALAPAGOS Stock

Certificat

FA76S

NLSGE001BNG5

Real-time Euronext Paris 03:23:53 2024-05-16 EDT
36.54 EUR +3.63% Intraday chart for CAPPED BONUS CERTIFICATE - GALAPAGOS
Current month+5.13%
1 month+0.51%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart GALAPAGOS NV
Chart CAPPED BONUS CERTIFICATE - GALAPAGOS

Latest news about GALAPAGOS NV

Galapagos Partners with Blood Centers of America to Decentralize CAR-T Cell Therapy Manufacture MT
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S. GL
Transcript : Galapagos NV, Q1 2024 Earnings Call, May 03, 2024
Galapagos : Galapagos reports first quarter 2024 financial results PU
More news

Quotes 5-day view

Date Price Change
24-05-16 36.54 +3.63%
24-05-15 35.26 +2.74%
24-05-14 34.32 -0.55%
24-05-13 34.51 +0.06%
24-05-10 34.49 -0.69%

Real-time Euronext Paris

Last update May 16, 2024 at 03:23 am

More quotes

Static data

Product typeCertificados de Bonus y Protección Parcial
Buy / SellCALL
Underlying GALAPAGOS NV
IssuerLogo Issuer Société Générale Société Générale
FA76S
ISINNLSGE001BNG5
Date issued 2023-08-21
Strike 42.3 €
Maturity 2024-12-20 (219 Days)
Parity 1 : 1
Emission price 36.02 €
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 39.53 €
Lowest since issue 32.87 €
Spread 0.6 €
Spread %1.69%

Company Profile

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Sector
-
More about the company

Ratings for Galapagos NV

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Galapagos NV

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
26.9 EUR
Average target price
37.03 EUR
Spread / Average Target
+37.66%
Consensus
  1. Stock Market
  2. Certificates
  3. FA76S Certificat
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**BENEFIT NOW**0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW